Mirati Therapeutics Net Income

Mirati Therapeutics (MRTX) currently reports a net income of $-720M as of September 2023. That compares with $-740M in the prior-year period — up 2.9% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Mirati Therapeutics's net income history and peer comparisons.

Mirati Therapeutics's net income increased from $-740M to $-720M — a 2.9% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics's net income of $-720M is lower than the Healthcare sector average of $16B. That is roughly 104.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mirati Therapeutics reported $-720M in net income as of September 2023. That compares with $-740M in the prior-year period — up 2.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-720M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.